EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Lung Cancer

Volumn 90, Issue 3, 2015, Pages 509-515

  Thress, Kenneth S ^a   Brant, Roz ^a   Carr, T Hedley ^a   Dearden, Simon ^a   Jenkins, Suzanne ^a   Brown, Helen ^a   Hammett, Tracey ^b   Cantarini, Mireille ^b   Barrett, J Carl ^a  

^a ASTRAZENECA   (United Kingdom)

^b Global Clinical Development   (United Kingdom)

Author keywords

AZD9291; Circulating tumor DNA; Epidermal growth factor receptor mutation; Non small cell lung cancer; T790M

Indexed keywords

CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; OSIMERTINIB; ACRYLAMIDE DERIVATIVE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; MULTICENTER STUDY; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; LUNG NEOPLASMS; MALE; MUTATION; POLYMERASE CHAIN REACTION; PROCEDURES; REPRODUCIBILITY; STANDARDS;

ACRYLAMIDES; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84949205332     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.10.004     Document Type: Article

References (33)

1. Fisher R., Pusztai L., Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 2013, 108:479-485.
2. Weber B., Meldgaard P., Hager H., Wu L., Wei W., Tsai J., et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer 2014, 14:294.
3. Arcila M.E., Oxnard G.R., Nafa K., Riely G.J., Solomon S.B., Zakowski M.F., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 2011, 17:1169-1180.
4. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3:75ra26.
5. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6:224ra24.
6. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
7. Douillard J.Y., Ostoros G., Cobo M., Ciuleanu T., Cole R., McWalter G., et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J. Thorac. Oncol. 2014, 9:1345-1353.
8. Douillard J.Y., Ostoros G., Cobo M., Ciuleanu T., McCormack R., Webster A., et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br. J. Cancer 2014, 110:55-62.
9. Mok T., Wu Y.L., Lee J.S., Yu C.-J., Sriuranpong V., Wen W., et al. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: a randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). J. Thorac. Oncol. 2013, 31. (Suppl:Abstract 8021).
10. Punnoose E.A., Atwal S., Liu W., Raja R., Fine B.M., Hughes B.G., et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 2012, 18:2391-2401.
11. Sun J.M., Karlovich C., Wen W., Wakelee H., Chien S., Mann E., et al. Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686. Mol. Cancer Ther. 2013, 12. (Suppl Abstract B25).
12. Gevensleben H., Garcia-Murillas I., Graeser M.K., Schiavon G., Osin P., Parton M., et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin. Cancer Res. 2013, 19:3276-3284.
13. Luo J., Shen L., Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci. Rep. 2014, 4:6269.
14. Vallee A., Marcq M., Bizieux A., Kouri C.E., Lacroix H., Bennouna J., et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 2013, 82:373-374.
15. Denis M.G., Vallee A., Theoleyre S. EGFR T790M resistance mutation in non small-cell lung carcinoma. Clin. Chim. Acta 2015, 444:81-85.
16. Ilie M., Hofman V., Long E., Bordone O., Selva E., Washetine K., et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?. Ann. Transl. Med. 2014, 2:107.
17. Cross D.A., Ashton S.E., Ghiorghiu S., Eberlein C., Nebhan C.A., Spitzler P.J., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014, 4:1046-1061.
18. Jänne P.A., Yang J.C., Kim D.W., Planchard D., Ohe Y., Ramalingam S.S., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:1689-1699.
19. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:357-360.
20. US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Devices and Radiological Health. Guidance for industry and FDA staff. Statistical guidance on reporting results from studies evaluating diagnostic tests. Rockville, MD: FDA, (2007).
21. Roche. cobas® EGFR Mutation Test, 2015. Available at (accessed on 13.03.15.). http://molecular.roche.com/assays/Pages/cobasEGFRMutationTest.aspx,
22. QIAGEN. therascreen EGFR RGQ PCR kit for the detection of mutations in the EGFR oncogene, 2015. Available at , (accessed on 13.03.15.). http://www.qiagen.com/gb/products/catalog/assay-technologies/complete-assay-kits/personalized-healthcare/therascreen-egfr-rgq-pcr-kit/.
23. Chen W.W., Balaj L., Liau L.M., Samuels M.L., Kotsopoulos S.K., Maguire C.A., et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol. Ther. Nucleic. Acids 2013, 2:e109.
24. Higgins M.J., Jelovac D., Barnathan E., Blair B., Slater S., Powers P., et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 2012, 18:3462-3469.
25. Holdhoff M., Schmidt K., Diehl F., Aggrawal N., Angenendt P., Romans K., et al. Detection of tumor DNA at the margins of colorectal cancer liver metastasis. Clin. Cancer Res. 2011, 17:3551-3557.
26. Beaver J.A., Jelovac D., Balukrishna S., Cochran R.L., Croessmann S., Zabransky D.J., et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res. 2014, 20:2643-2650.
27. Oxnard G.R., Paweletz C.P., Kuang Y., Mach S.L., O'Connell A., Messineo M.M., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20:1698-1705.
28. Finlay M.R., Anderton M., Ashton S., Ballard P., Bethel P.A., Box M.R., et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 2014, 57:8249-8267.
29. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19:2240-2247.
30. Katakami N., Atagi S., Goto K., Hida T., Horai T., Inoue A., et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 2013, 31:3335-3341.
31. Ramalingam S.S., Janne P.A., Mok T., O'Byrne K., Boyer M.J., Von Pawel J., et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014, 15:1369-1378.
32. Marcq M., Vallee A., Bizieux A., Denis M.G. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?. J. Thorac. Oncol. 2014, 9:e49-e50.
33. Shaw J.A., Stebbing J. Circulating free DNA in the management of breast cancer. Ann. Transl. Med. 2014, 2:3.